Abstract
Ipilimumab, cytotoxic T-lymphocyte-associated protein 4-blocking antibody, is known to precipitate tissue-specific immune-related adverse events. The second most common site for immune-related adverse events is the gastrointestinal tract, with toxic injury resulting in diarrhea, colitis, and enterocolitis. In the present case, a woman who received ipilimumab 2 weeks prior was found to have severe, diffuse corticosteroid-refractory gastrointestinal tract toxic injury affecting the stomach, small bowel, and colon.
MeSH terms
-
Abdominal Pain / diagnosis
-
Abdominal Pain / etiology
-
Biopsy, Needle
-
Colitis / chemically induced
-
Colitis / drug therapy
-
Colitis / pathology
-
Diarrhea / chemically induced
-
Diarrhea / drug therapy
-
Diarrhea / pathology
-
Emergency Service, Hospital
-
Endoscopy, Digestive System / methods
-
Female
-
Gastrointestinal Tract / drug effects*
-
Humans
-
Immunohistochemistry
-
Infusions, Intravenous
-
Ipilimumab / adverse effects*
-
Ipilimumab / therapeutic use
-
Melanoma / drug therapy*
-
Melanoma / pathology*
-
Methylprednisolone / therapeutic use
-
Neoplasm Invasiveness / pathology
-
Neoplasm Staging
-
Pain Measurement
-
Prognosis
-
Severity of Illness Index
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / pathology*
-
Treatment Outcome
-
Young Adult
Substances
-
Ipilimumab
-
Methylprednisolone